Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStephanie Fischingeren_US
dc.contributor.authorSally Shinen_US
dc.contributor.authorCarolyn M. Boudreauen_US
dc.contributor.authorMargaret Ackermanen_US
dc.contributor.authorSupachai Rerks-Ngarmen_US
dc.contributor.authorPunnee Pitisuttithumen_US
dc.contributor.authorSorachai Nitayaphanen_US
dc.contributor.authorJerome H. Kimen_US
dc.contributor.authorMerlin L. Robben_US
dc.contributor.authorNelson L. Michaelen_US
dc.contributor.authorRobert J. O'Connellen_US
dc.contributor.authorSandhya Vasanen_US
dc.contributor.authorHendrik Streecken_US
dc.contributor.authorGalit Alteren_US
dc.contributor.otherInternational Vaccine Institute, Seoulen_US
dc.contributor.otherUniversitäts-Klinikum Bonn und Medizinische Fakultäten_US
dc.contributor.otherThayer School of Engineering at Dartmouthen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherUniversität Duisburg-Essenen_US
dc.contributor.otherWalter Reed Army Institute of Researchen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHarvard Universityen_US
dc.contributor.otherHarvard and MGHen_US
dc.identifier.citationJCI insight. Vol.5, No.12 (2020)en_US
dc.description.abstractThe RV144 HIV-1 vaccine trial results showed moderate reduction in viral infections among vaccinees as well as induction of antibody-dependent cellular cytotoxicity and vaccine-specific IgG and IgG3 responses directed at variable loop regions 1 and 2 of the HIV envelope protein. However, with the recent failure of the HVTN 702 clinical trial, comprehensive profiling of humoral immune responses may provide insight for these disappointing results. One of the changes included in the HVTN 702 study was the addition of a late boost, aimed at augmenting peak immunity and durability. The companion vaccine trial RV305 was designed to permit the evaluation of the immunologic impact of late boosting with either the boosting protein antigen alone, the canarypox viral vector ALVAC alone, or a combination of both. Although previous data showed elevated levels of IgG antibodies in both boosting arms, regardless of ALVAC-HIV vector incorporation, the effect on shaping antibody effector function remains unclear. Thus, here we analyzed the antibody and functional profile induced by RV305 boosting regimens and found that although IgG1 levels increased in both arms that included protein boosting, IgG3 levels were reduced compared with the original RV144 vaccine strategy. Most functional responses increased upon protein boosting, regardless of the viral vector-priming agent incorporation. These data suggest that the addition of a late protein boost alone is sufficient to increase functionally potent vaccine-specific antibodies previously associated with reduced risk of infection with HIV.en_US
dc.rightsMahidol Universityen_US
dc.titleProtein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune responseen_US
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.